Anti-TNF antibodies, compositions, methods and uses
The present invention relates to methods for treating carcinomas or adenocarcinomas using at least one anti-TNF antibody.
1. A method for inhibiting TNF in a patient having colorectal carcinoma, pancreatic carcinoma, or nasopharyngeal carcinoma, comprising administering to said patient a composition comprising a TNF inhibiting effective amount of at least one isolated mammalian anti-TNF antibody comprising at least one heavy chain variable region comprising SEQ ID NO:7 and at least one light chain variable region comprising SEQ ID NO:8.
2. A method according to claim 1 , wherein said administering said at least one anti-TNF antibody is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, and intravenous.
3. A method according to claim 1 , wherein said method further comprises administering an effective amount of at least one anti-cancer therapeutic.
4. A method according to claim 1 , wherein said effective amount comprises a one time or repeated dose of 0.1-50 mg/kg.
5. A method for inhibiting TNF in a patient having an adenocarcinoma, comprising administering to said patient a composition comprising a TNF inhibiting effective amount of at least one isolated mammalian anti-TNF antibody comprising at least one heavy chain variable region comprising SEQ ID NO:7 and at least one light chain variable region comprising SEQ ID NO:8.
6. A method according to claim 5 , wherein said contacting or administering said at least one anti-TNF antibody is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, and intravenous.
7. A method according to claim 5 , wherein said method further comprises administering an effective amount of at least one anti-cancer therapeutic.
8. A method according to claim 5 , wherein said effective amount comprises a one time or repeated dose of 0.1-50 mg/kg.